BACKGROUND: Anemia of inflammation (AI, anemia of chronic disease) is an iron-restricted anemia caused by hepcidin limiting the supply of iron for erythropoiesis. We had previously shown that IL-6 was necessary for the induction of hepcidin and the development of hypoferremia during acute inflammation in vivo (Nemeth E et al, JCI, 2004). In vitro, IL-1 (Lee P et al, PNAS, 2005) and TGF-β (unpublished data) can also stimulate hepcidin production in primary murine hepatocytes in an IL-6 independent fashion.

METHODS: We sought to determine whether IL-6 was necessary for the development of AI using a model of chronic peritonitis in IL-6 deficient mice and wild type (WT) controls.

RESULTS: IL-6 deficient mice developed anemia of similar severity as their WT counterparts. WT mice developed microcytic anemia consistent with inflammation-induced iron restriction. In contrast, the inflamed IL-6 deficient mice developed mild macrocytosis indicating markedly different erythrocyte iron metabolism. Hepcidin mRNA increased in WT mice but not IL-6 deficient mice in response to inflammation.

CONCLUSION: IL-6 is the principal regulator of hepcidin during acute and chronic inflammation. However, anemia still occurs in the absence of IL-6. The difference in mean corpuscular volume implies that the mechanism of anemia in IL-6 deficient mice is likely different than in WT mice.

Author notes

Disclosure:Consultancy: T.G. provided consultancy to Xenon Pharmaceuticals, Burnaby, BC, and Roche, Basel, Switzerland. Ownership Interests: T.G. has ownership interest in Intrinsic Life Sciences, LLS, La Jolla, CA. Research Funding: Our lab receives funding from Amgen. The research contained in this abstract has no impact and does not utilize any product made by Amgen. Membership Information: Seth Rivera is on the Speakers Bureau for Baxter Pharmaceuticals. The research contained in this abstract has no impact and does not utilize any product made by Baxter.

Sign in via your Institution